Navigation Links
Fostamatinib proven to be safe but not effective

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe. Results of this phase II trial are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Patients with RA experience inflammation, pain and swelling of their joints that often limits daily activities and can lead to permanent disability. The National Arthritis Data Workgroup estimates that 1.3 million (0.6%) of adults in the U.S. have RA, affecting two to three times as many women as men. While many RA patients are successfully treated with disease-modifying anti-rheumatic drugs (DMARDs), those with moderate to severe RA may find that newer biologically-based therapies that inhibit cytokine activity, block T cell stimulation, or modify B cell biology slow disease progression, especially when combined with methotrexate (MTX). However, there remains a subgroup of the RA patient population who do not respond to DMARDs or current biologic therapies.

The three-month double-blind, placebo-controlled trial of R788, led by Mark Genovese, M.D., from Stanford University, enrolled 219 patients with active RA who failed to respond to one or more biologic therapies (TNF inhibitor, anakinra, abatacept, or rituximab). Patients were randomly assigned in a 2:1 ratio to receive 100 mg of R788 or placebo, respectively. Efficacy and safety were evaluated over three months. Researchers evaluated changes in the disease activity score (DAS); inflammation and joint damage were assessed by MRI.

"Our findings did not find an overall difference in efficacy between the small molecule drug, R788, and placebo," noted Dr. Genovese. "However, the drug was well tolerated and clinical benefit was found in only a subset of RA patients." Results showed that the primary outcome, the ACR 201 response, as well as the ACR 50 and 70 responses, were not significantly different between the group receiving R788 and the placebo group. However, in patients who entered the trial with an elevated C-reactive protein (CRP) level, analysis suggested a meaningful difference in the ACR 20 responses between the R788 (42%) and placebo (26%) groups. Additionally MRI results demonstrated improvement in joint inflammation in those patients with the greatest disease activity.

Researchers found that the 100mg dosage of R788 was well tolerated, with the most common adverse effects being nausea and diarrhea. "We found that 100mg of R788 was a tolerable dose for chronic administration in RA," concluded Dr. Genovese. "Phase III trials of R788 need to replicate our findings and identify subpopulations most likely to respond to this novel therapy."


Contact: Dawn Peters

Related medicine news :

1. Age 50 as mammography screening threshold proven unfounded
2. United Nations Foundation Commends G8 Leaders for Accelerating Support for Proven Interventions to Improve Women's and Children's Health
3. Little Known Proven Strategy to Increase Retirement Income by 25% or More to Be Revealed in Free Webinar Thursday, June 24
4. Use of unproven mammography tool soars with Medicare coverage
5. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
6. Online Body Transformation Contest Proven to be a Life Changer
7. Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful
8. Webinar Shares Proven Social Media Approach to BtoB Lead Generation
9. Biologic Joint Reconstruction Using Stem Cells Proven Successful In Patients With Arthritis
10. The Power of James Bond Symbols Proven by Dr. Emoto
11. Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses
Post Your Comments:
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... Scientists ... versus tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just ... , The doctors from PhenoPath Laboratories in Seattle and the University of British ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... new School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from ... education that has spanned four decades. , Dr. McLeod’s long and successful nursing ...
(Date:10/13/2015)... ... 13, 2015 , ... Breathing is one of the human ... According to T’ai Chi (also spelled “Taiji”) and Qigong Grand-masters Steven Aung, MD, ... with the 7,000 year old tradition they teach, can improve health, increase energy ...
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... Alpharetta, Georgia (PRWEB) , ... October 13, 2015 ... ... their leadership team: Debbie Vereb has been named the organization’s Executive Vice ... Tony Gerena, have been hired to key leadership roles in the company. , ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Center for Innovation announced today that Elizabeth ... th recipient of the CME Group Melamed-Arditti Innovation ... Theranos , to change health care from reactive to proactive, ... care. CME Group will present the award at the eighth ... Naples, Florida , on Tuesday, November 17. ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 ... new market research report "Spirometer Market by Product (Hand-held, Table-top, ... (Hospital, Clinic, Homecare), Application, & Geography - Global Forecast to ... reach USD 858.6 Million by 2020, at a CAGR of ... data Tables and 128 F igures spread th ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
Breaking Medicine Technology: